

**Distribution Coefficients for 5a and 5b.**—Ten milliliters each of  $C_6H_6$  and pH 7.4 Krebs–Ringers phosphate were shaken for 1 hr with the tritiated compound (5a and 5b). Each phase (1 ml) was counted in a liquid scintillation spectrometer. The counts per minute found in each phase were corrected to disintegrations per minute and the ratio was calculated.

**Hydrolytic Rate Studies on 16a and 16b.**—A 10-ml ethanolic 0.25 *N* NaOH solution containing 0.025 g of ester was maintained

at 21.5°. Aliquots (1 ml) were drawn at intervals and titrated with 0.04 *N* HCl using phenolphthalein as indicator. A blank experiment was carried out.

**Acknowledgment.**—We gratefully acknowledge support of this work by Public Health Service Grant GM 09402 from the National Institute of General Medical Sciences.

## Experimentally Induced Phenylketonuria. II. Potential Inhibitors of Phenylalanine Hydroxylase

JOSEPH I. DEGRAW, MICHAEL CORY, W. A. SKINNER, MYNA C. THEISEN, AND CHOZO MITOMA

*Departments of Pharmaceutical Chemistry and Biochemistry, Stanford Research Institute, Menlo Park, California 94025*


*Received September 18, 1967*

The preparation of a series of alkylating agents derived from phenylalanine is reported. The compounds were found to be ineffective as inhibitors of phenylalanine hydroxylase. Syntheses are described for 4-bromoacetyl-, 4-bromoacetamido-, 3-chloroacetamido-, and 4-fluoro-3-chloroacetamidophenylalanine.

In a previous publication<sup>1</sup> we reported an approach to the creation of a state of phenylketonuria (PKU) by inhibition of the enzyme, phenylalanine hydroxylase. We had confirmed earlier findings that 4-fluorophenylalanine<sup>2</sup> and esculetin (6,7-dihydroxycoumarin)<sup>3</sup> were good inhibitors of the enzyme *in vitro*. Our attempts to find a more potent inhibitor among a series of variously substituted phenylalanine derivatives were unsuccessful. However, we were able to conclude that alteration of the amino acid side chain and substitution of a group larger than fluorine in the 4 position was detrimental to activity. It appeared likely to us that irreversible inhibition of phenylalanine hydroxylase would more closely mimic the genetic defect responsible for PKU.


In the present work we have prepared some potential irreversible inhibitors in the form of alkylating agents derived from phenylalanine. The compounds were 4-bromoacetyl-, 4-bromoacetamido-, 3-chloroacetamido-, and 4-fluoro-3-chloroacetamidophenylalanine. As will be seen in the biological results, no significant degree of inhibition was realized with these compounds. Whether the lack of significant inhibition was due to the bulkiness of the haloalkyl substituents or insufficient reactivity of the alkylating functions is not known.

The synthesis of 4-bromoacetylphenylalanine started with 4-chloromethylacetophenone<sup>4</sup> (I) which was converted to the crude iodide (II), and this in turn was used to alkylate diethyl formamidomalonate (Chart I).




Acid hydrolysis and decarboxylation of the intermediate III yielded 4-acetylphenylalanine (IV). An effort was made to brominate IV directly in acetic acid at 70° but no reaction with bromine was observed. The N-carbobenzoxy derivative V was then prepared and brominated readily with trimethylphenylammonium tribromide<sup>5</sup> in THF to afford the N-carbobenzoxybromoketone (VI) in 44% yield. Treatment of VI with HBr–AcOH smoothly cleaved the blocking group without disturbance of the bromine to yield 4-bromoacetylphenylalanine (VII) as the hydrobromide salt.

4-Nitrophenylalanine was converted to its N-carbobenzoxy methyl ester. The nitro group was reduced and the resulting amine (XIa) was converted to the bromoacetamido compound (XIIa) (Chart II). Mild



a, 4-substituted phenyl  
b, 3-substituted phenyl  
c, 4-fluoro-3-substituted phenyl; chloroacetamides were prepared for the b and c series



exposure of XIIa to HBr–AcOH caused only partial removal of the methyl ester, while more vigorous conditions also caused cleavage of the bromoacetyl moiety.

(5) A. Marquet and J. Jacques, *Bull. Soc. Chim. France*, 90 (1962).

(1) J. I. DeGraw, M. Cory, W. A. Skinner, M. C. Theisen, and C. Mitoma, *J. Med. Chem.*, **10**, 64 (1967).

(2) D. D. Watt and J. P. Vandervoort, *Federation Proc.*, **23**, 146 (1964).

(3) S. B. Ross and O. Haljasmaa, *Life Sci.*, **3**, 579 (1964).

(4) L. Schmid, W. Swoboda, and M. Wichtl, *Monatsh.*, **83**, 185 (1952).

Careful saponification of the ester with alkali yielded the *N*-carbobenzoxy acid (XIIIa) and subsequent treatment with HBr–AcOH afforded 4-bromoacetamido-phenylalanine (XIVa).

It was found necessary to prepare 3-chloroacetamido-phenylalanine (XIVb) rather than the planned bromo analog since alkaline hydrolysis of the 3-bromoacetamido ester (XV) could not be effected without partial loss of the bromo group. The synthesis was similar to that of XIVa and began with 3-nitrophenylalanine.<sup>6</sup>

3-Chloroacetamido-4-fluorophenylalanine (XIVc) was also prepared from 4-fluoro-3-nitrophenylalanine (VIIIc) in a manner analogous to that described above. The reduction of 4-fluoro-3-nitrobenzoic acid (XVI)<sup>7</sup> with diborane afforded 4-fluoro-3-nitrobenzyl alcohol (XVII). The alcohol was converted to the chloride (XVIII), which was used to alkylate diethyl acetamidomalonalate. Hydrolysis of the intermediate amido diester (XIX) with concentrated HCl yielded 4-fluoro-3-nitrophenylalanine (VIIIc).

**Biological Evaluation.**—Phenylalanine hydroxylase was prepared from rat liver by the method of Kaufman;<sup>8</sup> purification was carried out up to step 2 of his procedure. The incubation mixture consisted of 100  $\mu$ moles of sodium phosphate buffer, pH 7.4, 2.0  $\mu$ moles of reduced diphosphopyridine nucleotide, 10  $\mu$ moles of nicotinamide, approximately 10 mg of enzyme protein, 1.0  $\mu$ mole of phenylalanine, and appropriate amounts of the test compound in a final volume of 1.74 ml. Incubation was carried out for 20 min at 37° in air. Tyrosine was assayed by the method of Udenfriend and Cooper.<sup>9</sup>

All of the phenylalanine-derived alkylating agents (VII, XIVa–c) showed less than 50% inhibition at a ratio of substrate to inhibitor of 1:1. Prior investigation<sup>1</sup> showed that esculetin and 4-fluorophenylalanine gave 50% inhibition of phenylalanine hydroxylase at ratios of 200:1 and 10:1, respectively.

## Experimental Section

Where analyses are indicated only by symbols of the elements, the analytical results obtained for those elements were within  $\pm 0.4\%$  of the theoretical values. Melting points were determined on a Fischer-Johns apparatus and are corrected.

**Diethyl 4-Acetylbenzylformamidomalonalate (III).**—To 10.5 g (63.3 mmole) of *p*-(chloromethyl)acetophenone (I)<sup>4</sup> in 250 ml of Me<sub>2</sub>CO was added 34.8 g (0.316 mole) of NaI. The suspension was stirred at reflux for 16 hr and evaporated *in vacuo* to dryness. The crude mixture was partitioned between 200 ml of CHCl<sub>3</sub> and 200 ml of H<sub>2</sub>O. The CHCl<sub>3</sub> layer was washed (two 100-ml portions of H<sub>2</sub>O), dried (MgSO<sub>4</sub>), and evaporated *in vacuo* to yield 15.1 g of II as a light yellow solid (91%). The crude iodide was dissolved in 100 ml of EtOH and added to 1.35 g (58.1 mg-atoms) of Na and 11.82 g (58.1 mmole) of diethyl formamidomalonalate in 200 ml of EtOH. The resulting solution was heated at reflux for 3 hr and evaporated to near dryness, and H<sub>2</sub>O (100 ml) was added. The crystalline precipitate that resulted was washed (H<sub>2</sub>O), dried in air, and recrystallized (EtOH) to yield 7.5 g (39%) of white crystals, mp 131.5–133.5°. *Anal.* (C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>6</sub>) C, H, N.

**4-Acetylphenylalanine Hydrochloride (IV).**—A solution of 0.59 g (1.7 mmole) of III in 2.2 ml of concentrated HCl was heated at reflux for 16 hr and evaporated *in vacuo* to dryness. The residue was dissolved in concentrated NH<sub>4</sub>OH and filtered. The filtrate was acidified to pH 1, chilled, and filtered. The product was recrystallized from 95% EtOH to yield 0.28 g (63%) of white

crystals, mp 182–185° dec. *Anal.* (C<sub>11</sub>H<sub>13</sub>NO<sub>3</sub>·HCl·0.5H<sub>2</sub>O) C, H, N.

***N*-Carbobenzoxy-4-acetylphenylalanine (V).**—To 1.00 g (4.8 mmole) of IV in 25 ml of 10% K<sub>2</sub>CO<sub>3</sub> at 0° was added 1.65 g (9.6 mmole) of carbobenzoxy chloride over 10 min with stirring. The mixture was stirred 3 hr, washed (three 20-ml portions of CHCl<sub>3</sub>), and acidified with 6 *N* HCl to pH 1. The gum was extracted into 50 ml of CHCl<sub>3</sub>, then washed with two 20-ml portions of H<sub>2</sub>O. The CHCl<sub>3</sub> extract was dried (MgSO<sub>4</sub>) and evaporated *in vacuo* to dryness. The resulting crystals were recrystallized twice from EtOAc–cyclohexane (1:5) to yield 0.86 g (52%) of white crystals, mp 119.5–121.5°. *Anal.* (C<sub>15</sub>H<sub>15</sub>NO<sub>3</sub>) C, H, N.

***N*-Carbobenzoxy-4-bromoacetylphenylalanine (VI).**—To a solution of 2.96 g (8.7 mmole) of V in 60 ml of THF was added 3.17 g (8.6 mmole) of trimethylphenylammonium tribromide. The orange solution was stirred overnight. The resulting pale yellow mixture was filtered and evaporated *in vacuo* to dryness to yield a light yellow solid. Two recrystallizations (C<sub>6</sub>H<sub>6</sub>) afforded 1.6 g (44%) of white crystals, mp 144–146°. *Anal.* (C<sub>15</sub>H<sub>13</sub>BrNO<sub>3</sub>) C, H, N, Br.

**4-Bromoacetylphenylalanine Hydrobromide (VII).**—To 0.50 g (1.2 mmole) of VI was added 2 ml of 30% HBr in AcOH. The solution was stirred at room temperature for 1 hr and evaporated *in vacuo* to dryness. The white crystalline residue that remained was triturated with Et<sub>2</sub>O (20 ml) and filtered. (See Table II for physical data.)

**4-Fluoro-3-nitrophenylalanine Hydrochloride (VIIIc).**—Following the procedure for 4-acetylphenylalanine hydrochloride (IV), 1.0 g (2.7 mmole) of diethyl 4-fluoro-3-nitrobenzylacetamidomalonalate (XIX) was hydrolyzed with 15 ml of concentrated HCl to yield, after recrystallization from 95% AcOH, 0.57 g (79%) of white crystals, mp 203–205°. *Anal.* (C<sub>9</sub>H<sub>8</sub>FN<sub>2</sub>O<sub>4</sub>·HCl) C, H, N.

**Methyl 4-Nitrophenylalanate Hydrochloride (IXa).**—To 30 ml of MeOH saturated at 0° with dry HCl was added 3.0 g (14.3 mmole) of 4-nitrophenylalanine (Cyclo Chemical Co.). The resulting solution was stirred at reflux for 16 hr, cooled to room temperature, and evaporated *in vacuo* to dryness. Recrystallization from MeOH gave 2.5 g (77%) of white crystals, mp 213–214°. *Anal.* (C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>·HCl) C, H, N.

**Methyl 3-nitrophenylalanate hydrochloride (IXb)** was prepared by the procedure for IXa. The product, mp 182.5–184°, was obtained in an 82% yield after recrystallization from MeOH. *Anal.* (C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>·HCl) C, H, N.

**Methyl 4-fluoro-3-nitrophenylalanate hydrochloride (IXc)** was prepared from 3-nitrophenylalanine<sup>6</sup> following the procedure for IXa; mp 192.5–194°, yield 83%, after recrystallization from MeOH. *Anal.* (C<sub>10</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>4</sub>·HCl) C, H, N.

**Methyl *N*-Carbobenzoxyphenylalanates (X).**—To an ice-cold mixture of 0.05 mole of the substituted phenylalanine methyl ester hydrochloride in H<sub>2</sub>O (400 ml) containing 0.30 mole of K<sub>2</sub>CO<sub>3</sub> was added 0.10 mole of carbobenzoxy chloride in 400 ml of CHCl<sub>3</sub> at 0°. The mixture was stirred at 0° for 1 hr and at room temperature for 3 hr. The CHCl<sub>3</sub> was washed (three 50-ml portions of H<sub>2</sub>O), three 50-ml portions of 3 *N* HCl, three 50-ml portions of H<sub>2</sub>O, dried (MgSO<sub>4</sub>), and evaporated *in vacuo*. The resulting products were collected and recrystallized (see Table I).

**Methyl *N*-Carbobenzoxyaminophenylalanates (XI).**—To a solution of 1.5 mmole of the methyl *N*-carbobenzoxyphenylalanate in 15 ml of 90% MeOH at 40° was added 2.5 mmole of NH<sub>4</sub>Cl followed slowly by 15.0 mg-atoms of Zn dust. The mixture was stirred at reflux for 3 hr, filtered while hot, and evaporated *in vacuo* to dryness. The residual mixture was partitioned between ether and water, and the Et<sub>2</sub>O was dried and evaporated *in vacuo* to dryness. The resulting gum was used directly for the next reaction. In some cases picrates were prepared for analytical purposes as recorded in Table I.

**Methyl *N*-Carbobenzoxy- $\alpha$ -haloacetamidophenylalanates (XII).**—To a suspension of 120 mmole of powdered, anhydrous K<sub>2</sub>CO<sub>3</sub> in 15 ml of C<sub>6</sub>H<sub>6</sub> containing 6.0 mmole of the methyl *N*-carbobenzoxyaminophenylalanate was slowly added 6.5 mmole of either chloroacetyl chloride or bromoacetyl bromide keeping the temperature between 15–20°. The mixture was stirred at room temperature for 3 hr and chilled to 5°, and 25 ml of H<sub>2</sub>O was added. The benzene was separated, washed (three 10-ml portions of H<sub>2</sub>O), three 20-ml portions of 3 *N* HCl, three 10-ml portions of H<sub>2</sub>O, dried (MgSO<sub>4</sub>), and evaporated *in vacuo* to dryness. The product was collected and recrystallized (see Table I).

(6) H. F. Gram, C. W. Mosher, and B. R. Baker, *J. Am. Chem. Soc.*, **81**, 3103 (1959).

(7) H. Hopff and G. Valkunas, *J. Org. Chem.*, **27**, 2923 (1962).

(8) S. Kaufman, *Methods Enzymol.*, **5**, 809 (1962).

(9) S. Udenfriend and J. R. Cooper, *J. Biol. Chem.*, **196**, 227 (1952).

TABLE I  
SUBSTITUTED N-CARBOBENZOXYPHENYLALANINES  
ArCH<sub>2</sub>CHCO<sub>2</sub>R

No.	Ar	R	Yield, %	Mp, °C	Crystn solvent	Formula	Analyses
Xa	4-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	72	77.5–78.5	C <sub>6</sub> H <sub>6</sub> -cyclohexane	C <sub>18</sub> H <sub>18</sub> N <sub>2</sub> O <sub>6</sub>	C, H, N
Xb	3-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	86	49–52	C <sub>6</sub> H <sub>6</sub> -hexane	C <sub>18</sub> H <sub>18</sub> N <sub>2</sub> O <sub>6</sub>	C, H, N
Xc	3-NO <sub>2</sub> -4-FC <sub>6</sub> H <sub>3</sub>	CH <sub>3</sub>	83	64.5–67	C <sub>6</sub> H <sub>6</sub> -cyclohexane	C <sub>18</sub> H <sub>17</sub> FN <sub>2</sub> O <sub>6</sub>	C, H, N
XIa	4-NH <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	92 <sup>a</sup>	128–130	50% EtOH	C <sub>24</sub> H <sub>23</sub> N <sub>3</sub> O <sub>11</sub>	C, H, N
XIb	3-NH <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	90 <sup>a</sup>	169–171	50% MeOH	C <sub>24</sub> H <sub>23</sub> N <sub>3</sub> O <sub>11</sub>	C, H, N
XIc	3-NH <sub>2</sub> -4-FC <sub>6</sub> H <sub>3</sub>	CH <sub>3</sub>	95 <sup>b</sup>				
XIIa	4-NHCOCH <sub>2</sub> BrC <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	31	100–102	C <sub>6</sub> H <sub>6</sub> -cyclohexane	C <sub>20</sub> H <sub>21</sub> BrN <sub>2</sub> O <sub>5</sub>	C, H, N
XIIb	3-NHCOCH <sub>2</sub> ClC <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	45	82–84	C <sub>6</sub> H <sub>6</sub> -cyclohexane	C <sub>20</sub> H <sub>21</sub> ClN <sub>2</sub> O <sub>5</sub>	C, H, Cl, N
XIIc	3-NHCOCH <sub>2</sub> Cl-4-FC <sub>6</sub> H <sub>3</sub>	CH <sub>3</sub>	41	84–85	C <sub>6</sub> H <sub>6</sub> -cyclohexane	C <sub>20</sub> H <sub>20</sub> ClFN <sub>2</sub> O <sub>5</sub>	C, H, N
XIIIa	4-NHCOCH <sub>2</sub> BrC <sub>6</sub> H <sub>4</sub>	H	61	154–155.5	C <sub>6</sub> H <sub>6</sub> -EtOAc	C <sub>19</sub> H <sub>19</sub> BrN <sub>2</sub> O <sub>5</sub>	C, H, Br, N
XIIIb	3-NHCOCH <sub>2</sub> ClC <sub>6</sub> H <sub>4</sub>	H	42	116.5–120	C <sub>6</sub> H <sub>6</sub>	C <sub>19</sub> H <sub>19</sub> ClN <sub>2</sub> O <sub>5</sub>	C, H, Cl, N
XIIIc	3-NHCOCH <sub>2</sub> Cl-4-FC <sub>6</sub> H <sub>3</sub>	H	75	145–147	EtOAc	C <sub>19</sub> H <sub>18</sub> ClFN <sub>2</sub> O <sub>5</sub>	C, H, Cl, N
XV	3-NHCOCH <sub>2</sub> BrC <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	25	90–93	C <sub>6</sub> H <sub>6</sub>	C <sub>20</sub> H <sub>21</sub> BrN <sub>2</sub> O <sub>5</sub>	C, H, N

<sup>a</sup> Yield as free base; characterized as picrate. <sup>b</sup> Crude oil used for next reaction without analysis.

TABLE II  
SUBSTITUTED PHENYLALANINES  
ArCH<sub>2</sub>CHCO<sub>2</sub>H

No.	Ar	Yield, %	Mp, °C	Crystn solvent	Formula	Analyses
VII	4-COCH <sub>2</sub> BrC <sub>6</sub> H <sub>4</sub>	68	210.5–212	95% AcOH	C <sub>11</sub> H <sub>12</sub> BrNO <sub>3</sub> ·HBr	C, H, Br, N
XIVa	4-NHCOCH <sub>2</sub> BrC <sub>6</sub> H <sub>4</sub>	57	243–245	95% EtOH	C <sub>11</sub> H <sub>13</sub> BrN <sub>2</sub> O <sub>3</sub> ·HBr	C, H, N
XIVb	3-NHCOCH <sub>2</sub> ClC <sub>6</sub> H <sub>4</sub>	51	>300	Me <sub>2</sub> CO–Et <sub>2</sub> O	C <sub>11</sub> H <sub>13</sub> ClN <sub>2</sub> O <sub>3</sub> ·HBr	C, H, N
XIVc	3-NHCOCH <sub>2</sub> Cl-4-FC <sub>6</sub> H <sub>3</sub>	78 <sup>a</sup>	287–292	Me <sub>2</sub> CO–Et <sub>2</sub> O	C <sub>11</sub> H <sub>12</sub> ClFN <sub>2</sub> O <sub>3</sub> ·HBr·HOAc	C, H, N

<sup>a</sup> Compound quite hygroscopic.

**N-Carbobenzoxy- $\alpha$ -haloacetamidophenylalanines (XIII).**—To 1.0 mmole of the methyl N-carbobenzoxy- $\alpha$ -haloacetamidophenylalanine in 20 ml of MeOH at 0° was added 1.0 ml of 1.00 N KOH. The resulting solution was stirred at room temperature until the pH was approximately 7 (about 5 hr). Tests with acidic, alcoholic AgNO<sub>3</sub> were run upon the reaction solution at 1-hr intervals. In the case of the methyl N-carbobenzoxy-3-bromoacetamidophenylalanate (XV) a positive halide test resulted after 1 hr. The reaction mixture was evaporated *in vacuo* to dryness and the resulting gum was partitioned between CHCl<sub>3</sub> and saturated NaHCO<sub>3</sub>. The NaHCO<sub>3</sub> extract was acidified to pH 1 with 3 N HCl, extracted with CHCl<sub>3</sub>, dried (MgSO<sub>4</sub>), and evaporated *in vacuo* to dryness. The products were collected and recrystallized (see Table I).

**$\alpha$ -Haloacetamidophenylalanines (XIV)** were all prepared from the respective N-carbobenzoxy acids (XIII) by the same procedure used for 4-bromoacetylphenylalanine (VII) (see Table II).

**4-Fluoro-3-nitrobenzyl Alcohol (XVII).**—To 20 ml (20 mmoles) of 1 M borane in THF at 0° was slowly added 1.85 g (10 mmoles) of 4-fluoro-3-nitrobenzoic acid (XVI) in 25 ml of THF. The mixture was stirred at reflux for 1 hr and chilled to 0–5°. Five milliliters of 3 N HCl was added slowly and the mixture was evaporated *in vacuo* to dryness. The resulting solid was par-

tituted between H<sub>2</sub>O and Et<sub>2</sub>O, and Et<sub>2</sub>O extract was washed (three 10-ml portions of saturated NaHCO<sub>3</sub>, three 10-ml portions of H<sub>2</sub>O), dried (MgSO<sub>4</sub>), and evaporated *in vacuo* to yield 1.5 g (87%) of a yellow oil. A portion of the oil was purified for analysis by glpc on a 16.3 × 0.62 cm column of 20% DC 550 on Chromosorb W 45/60 at 185°. *Anal.* (C<sub>7</sub>H<sub>6</sub>FN<sub>2</sub>O<sub>3</sub>) C, H, N.

**4-Fluoro-3-nitrobenzyl Chloride (XVIII).**—To 7.6 g (44 mmoles) of 4-fluoro-3-nitrobenzyl alcohol (XVII) was added 41.5 g (0.349 mole) of SOCl<sub>2</sub>. The solution was stirred at room temperature for 1 hr and distilled *in vacuo* through a 10-cm Vigreux head to yield 6.24 g (74%) of colorless oil, bp 111–112° (1.2 mm). *Anal.* (C<sub>7</sub>H<sub>5</sub>ClFNO<sub>2</sub>) C, H, N.

**Diethyl 4-Fluoro-3-nitrobenzylacetamidomalonate (XIX).**—Following the procedure for III, 1.16 g (6.2 mmoles) of XVIII was treated with 4.59 g (30.8 mmoles) of NaI in 50 ml of Me<sub>2</sub>CO. The crude iodide was allowed to react with a solution of 0.14 g (6.2 mg-atoms) of Na and 1.34 g (6.2 mmoles) of diethyl acetamidomalonate in 50 ml of EtOH to yield, after recrystallization from EtOH, 1.42 g (62%) of white crystals, mp 121.5–123°. *Anal.* (C<sub>16</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>7</sub>) C, H, N.

**Acknowledgment.**—This work was supported by Public Health Service Grant HD 01972.